LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

Search

Puma Biotechnology Inc

Suletud

SektorTervishoid

6.57 -4.51

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

6.57

Max

6.98

Põhinäitajad

By Trading Economics

Sissetulek

3M

8.8M

Müük

2M

54M

P/E

Sektori keskmine

9.297

121.746

Kasumimarginaal

16.235

Töötajad

172

EBITDA

2.7M

13M

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

26. veebr 2026

Turustatistika

By TradingEconomics

Turukapital

93M

347M

Eelmine avamishind

11.08

Eelmine sulgemishind

6.57

Uudiste sentiment

By Acuity

20%

80%

35 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Puma Biotechnology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. veebr 2026, 23:26 UTC

Suurimad hinnamuutused turgudel

Moderna Stock Slips After FDA Refuses Flu Vaccine Review

10. veebr 2026, 22:31 UTC

Tulu

Correction to America Movil 4Q Profit Article

10. veebr 2026, 22:22 UTC

Tulu

America Movil 4Q Profit Jumps on Lower Financial Costs

10. veebr 2026, 23:51 UTC

Market Talk
Tulu

Commonwealth Bank's Margin Management Gives It a Platform -- Market Talk

10. veebr 2026, 23:42 UTC

Market Talk

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

10. veebr 2026, 23:40 UTC

Market Talk
Tulu

Commonwealth Bank Bear Says 1H Result Looks Strong -- Market Talk

10. veebr 2026, 23:21 UTC

Market Talk

Ford Says EV Shift Was Driven by Demand Changes -- Market Talk

10. veebr 2026, 23:21 UTC

Market Talk

Global Equities Roundup: Market Talk

10. veebr 2026, 22:17 UTC

Market Talk

Australia's One Nation Now Commands Working Class Vote -- Market Talk

10. veebr 2026, 22:15 UTC

Tulu

Humana Earnings Will Shed More Light on Medicare Prospects -- Barrons.com

10. veebr 2026, 22:10 UTC

Tulu

Intact Financial 4Q Book Value Per Share Was C$107.35 >IFC.T

10. veebr 2026, 22:10 UTC

Tulu

Intact Financial Raises Qtr Dividend to C$1.47 >IFC.T

10. veebr 2026, 22:09 UTC

Tulu

Intact Financial 4Q Combined Ratio Was 85.9% >IFC.T

10. veebr 2026, 22:09 UTC

Tulu

Intact Financial 4Q Adj EPS C$5.50 >IFC.T

10. veebr 2026, 22:01 UTC

Tulu

Intact Financial 4Q EPS C$5.24 >IFC.T

10. veebr 2026, 21:54 UTC

Tulu

James Hardie Industries Sees FY26 Total Adjusted EBITDA $1.232B to $1.263B >JHX

10. veebr 2026, 21:53 UTC

Tulu

Robinhood Stock Tumbles as Crypto-Related Revenue Falls Short of Expectations -- Barrons.com

10. veebr 2026, 21:51 UTC

Tulu

James Hardie Industries Sees FY26 Free Cash Flow at Least $200M

10. veebr 2026, 21:51 UTC

Tulu

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10. veebr 2026, 21:51 UTC

Tulu

James Hardie Industries: Focused on the Achievement of $125 M Target >JHX

10. veebr 2026, 21:51 UTC

Tulu

James Hardie Industries: Integration and Cost Synergies Ahead of Schedule >JHX

10. veebr 2026, 21:51 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Evolution Net Debt A$362 Million at Dec. 31 Vs A$1.29 Billion Year Earlier

10. veebr 2026, 21:50 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Evolution: Gearing 6% at Dec. 31, From 23% a Year Earlier

10. veebr 2026, 21:50 UTC

Tulu

James Hardie Industries 3Q EPS 12c >JHX

10. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

10. veebr 2026, 21:50 UTC

Tulu

James Hardie Industries 3Q Adj EPS 24c >JHX

10. veebr 2026, 21:49 UTC

Tulu

James Hardie Industries 3Q Sales $1.24B >JHX

10. veebr 2026, 21:49 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Evolution 1H Operating Mine Cash Flow a Record A$1.73 Billion

10. veebr 2026, 21:48 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Evolution 1H Ebitda A$1.56 Billion, Up 59% On-Year

10. veebr 2026, 21:47 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Evolution 1H Revenue A$2.79 Billion, Up 37% On-Year

Võrdlus sarnastega

Hinnamuutus

Puma Biotechnology Inc Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

0

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.07 / 3.075Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

35 / 352 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
help-icon Live chat